Tepotinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 245 publications

Repurposing FDA-Approved Drugs to Inhibit Fungal PPTases for Broad-Spectrum Synergy.

Repurposing FDA-Approved Drugs to Inhibit Fungal PPTases for Broad-Spectrum Synergy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: June 12, 2026

1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL.

1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL.

Journal: Cells

Published: May 22, 2026

Risk of peripheral edema in cancer patients receiving MET inhibitors: a systematic review and meta-analysis.

Risk of peripheral edema in cancer patients receiving MET inhibitors: a systematic review and meta-analysis.

Journal: Journal of chemotherapy (Florence, Italy)

Published: May 03, 2026

Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.

Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: May 01, 2026

Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.

Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.

Journal: Cancer science

Published: April 08, 2026

Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.

Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.

Journal: Lung cancer management

Published: April 04, 2026

Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer.

Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer.

Journal: Therapeutic advances in medical oncology

Published: March 26, 2026

A novel c-Met inhibitor containing chiral pyrrolidine side chain and its application as anti-tumor agents.

A novel c-Met inhibitor containing chiral pyrrolidine side chain and its application as anti-tumor agents.

Journal: European journal of medicinal chemistry

Published: March 02, 2026

Large-scale transcriptomic data mining using explainable XGBoost and SHAP reveals shared biomarkers and molecular mechanisms between type-2 diabetes and triple-negative breast cancer for drug repurposing.

Large-scale transcriptomic data mining using explainable XGBoost and SHAP reveals shared biomarkers and molecular mechanisms between type-2 diabetes and triple-negative breast cancer for drug repurposing.

Journal: BioData mining

Published: February 21, 2026

Knockdown of FAXDC2 promotes cell proliferation, migration, invasion and EMT in HepG2 cells by upregulating c-Met and its phosphorylation.

Knockdown of FAXDC2 promotes cell proliferation, migration, invasion and EMT in HepG2 cells by upregulating c-Met and its phosphorylation.

Journal: Molecular biology reports

Published: February 11, 2026

A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.

A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.

Journal: Renal failure

Published: January 25, 2026

Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.

Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.

Journal: Journal of translational medicine

Published: January 19, 2026

Showing 1-12 of 245

Last Updated: 09/26/2026